Beneficial clinical effects of cyclosporin A on severe psoriasis and its dissociation from serum concentration of soluble interleukin-2 receptor, soluble interleukin-6 receptor, soluble CD14 antigen, soluble intercellular adhesion molecule-1, and soluble vascular cell adhesion molecule-1.
Yamamoto
T
T
Department of Dermatology, Tokyo Medical and Dental University, Japan.
Kimura
K
K
Katayama
I
I
Koyano
T
T
Mamada
A
A
Miyazaki
K
K
Irimajiri
T
T
Furuse
Y
Y
Nishioka
K
K
D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism; D016572:Cyclosporine / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D015850:Interleukin-6 / Q000378:metabolism; D018950:Lipopolysaccharide Receptors / Q000097:blood; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology*; D018123:Receptors, Interleukin / Q000378:metabolism; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D019947:Receptors, Interleukin-6; D012995:Solubility; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood
D015703:Antigens, CD; D007166:Immunosuppressive Agents; D015850:Interleukin-6; D018950:Lipopolysaccharide Receptors; D018123:Receptors, Interleukin; D015375:Receptors, Interleukin-2; D019947:Receptors, Interleukin-6; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1; D016572:Cyclosporine